Pharmacology of the Cardiovascular and Central Nervous Systems

 

 

 

111.    The following drug interactions may occur in patients with monoamine oxidase (MAO) inhibitors:

a.    T

b.    F

c.    F: A hypertensive response is more likely.

d.    F: A potentiation of the hypoglycaemic response to tolbutamide may occur, as MAO inhibitors inhibit enzymes other than MAO thus slowing the metabolism of tolbutamide.

e.    T

 

 

112.    Tricyclic antidepressants such as imipramine:

 

a.     F

b.     T

c.     F

d.     T

e.     T

 

 

113.    Methylxanthines:

 

a.     T

b.     T

c.     T

d.     T

e.     T

 

 

114.    The following act as dopamine-receptor agonists:

a.      F: metoclopramide selectively blocks dopamine receptors associated with drug-induced nausea and emesis and is used as an anti-emetic.

b.      F

c.      T

d.      F

e.      T

 

 

115.    Blockade of dopamine receptors:

 

a.      T: the dopamine theory of psychosis states that there may be overactivity of certain dopaminergic pathways.

b.      T

c.      T: dopamine inhibits release of prolactin from the anterior pituitary; uncontrolled release of dopamine following receptor blockade leads to inhibition of release of gonadotrophic hormone-releasing factors which causes infertility.

d.      T

e.      F

 

 

116.     Vomiting can be caused by:

 

a.      F: stimulation of dopamine receptors in the chemoreceptor trigger zone causes vomiting.

b.      F: metoclopramide blocks dopamine receptors and can prevent vomiting induced by dopamine agonists.

c.      T: ipecacuanha and cardiac glycosides cause vomiting by acting both in the chemoreceptor trigger zone and in the gastrointestinal tract.

d.      F: 5-HT3 antagonists, for example odansetron, are highly effective antiemetics particularly effective in the treatment of vomiting caused by chemotherapy and radiotherapy.

e.      F

 

 

117.    Dopa decarboxylase:

 

a.      T: it is found in all cells in the body.

b.      F

c.      T

d.      T

e.      T

 

 

118.     When L-dopa is used in the treatment of Parkinson's disease it:

 

a.      F

b.      T

c.      F

d.      T

e.      T

 

 

119.    The following drugs, by affecting dopaminergic mechanisms, can have the actions indicated:

 

a.      T

b.      F: reserpine will induce a Parkinsonian syndrome.

c.      T

d.      T

e.      T: mazindol causes dopamine release and inhibits its re-uptake into neurons.

 

 

 

120.    Chlorpromazine:

 

a.      F

b.      T

c.      T

d.      T

e.      F: chlorpromazine causes a gain in weight and an increase in appetite.

 

 

<< Last Page                       Questions                         Next Page >>

Hosted by www.Geocities.ws

1